Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorBeijing Institute of Heart, Lung and Blood Vessel Diseases
About this trial
The registry study aims to determine serial biomarkers to diagnosis and prognosis of aortic aneurysm/aortic dissection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients who were referred to the surgical service for evaluation and management of aortic dissection were included.
Patients with initial suspicion of having AAD were perspectively enrolled.
Disqualifiers
Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;
Patients with aortic trauma, pseudo aneurysm, history of heart failure, renal dysfunction, severe pulmonary diseases, or active cancer;
Patients who entered the hospital for checkups after surgery.
Patients in whom there is little or no suspicion of a life-threatening disease;
Trial population
These cohorts consist of patients who was diagnosed as thoracic aortic aneurysm/dissection or initial suspicion of having thoracic aortic aneurysm/dissection.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
1,500 Participants
are grouped into 3 trial groupsGroup A: Top third of subjects based levels of selected biomarker.
Group B: Middle third of subjects based levels of selected biomarker.
Group C: Bottom third ofsubjects based levels of selected biomarker.
Trial outcomes
Primary outcomes
1
Dignosis of each participant
1. Patients with Aneurysm/Dissection had image information from ultrasound cardiograms and computed tomography to confirm the final diagnosis. 2. AMI if they had chest pain lasting \>20 min, diagnostic serial ECG changes comprising new pathological Q waves or ST-segment and T-wave changes, and a plasma creatine kinase-MB elevation greater than twice the normal level or cardiac troponin I (cTnI) level greater than 0.1 ng/mL. 3. Diagnosis of PE was confirmed by positive spiral computed tomography or pulmonary angiography, a high probability on ventilation perfusion scintigraphy, or a proximal deep vein thrombosis documented on compression ultrasonography or angiography.
Time frame
These data is collected from the cases' medical record in an average of 6 month after the sample recruiting2
Prognosis of each participant
Prognosis information including all-cause mortality and in-hospital mortality.
Time frame
These data is collected from the cases' medical record or during follow-up visit at 2-4 years after discharge.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead sponsor
Beijing Luhe Hospital
Collaborator
The First Affiliated Hospital of Dalian Medical University
Collaborator
The First Hospital of Jilin University
Collaborator
First Affiliated Hospital, Sun Yat-Sen University
Collaborator
The General Hospital of Northern Theater Command
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
Source ClinicalTrials.gov